AVEO Pharmaceuticals Inc operates as a biopharmaceutical company, which is engaged in the advancement of therapeutics for oncology and other areas of unmet medical need. The company views its operations and manages its business in the US. The firm offers products such as Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. Tivozanib is designed to optimize vascular endothelial growth factor blockade while minimizing off-target toxicities, Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity, AV-380, a humanized inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.